Co­herus ex­its TIG­IT deal with Jun­shi, three months af­ter Sur­face On­col­o­gy buy­out

Co­herus Bio­Sciences is walk­ing away from a three-year TIG­IT pact with Shang­hai Jun­shi Bio­sciences, sev­er­al months af­ter it ac­quired Sur­face On­col­o­gy and its TIG­IT drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER